
1. j antimicrob chemother. 2020 jul 1;75(7):1766-1771. doi: 10.1093/jac/dkaa092.

impact first-line treatment shift dihydroartemisinin/piperaquine to
artesunate/mefloquine plasmodium vivax drug susceptibility cambodia.

roesch c(1)(2), mairet-khedim m(1)(2), kim s(1)(2), lek d(3), popovici j(1)(2),
witkowski b(1)(2).

author information: 
(1)malaria molecular epidemiology unit, institut pasteur du cambodge, phnom penh,
cambodia.
(2)malaria translational research unit, institut pasteur, paris & institut
pasteur du cambodge, phnom penh, cambodia.
(3)national center malariology, entomology malaria control, phnom penh,
cambodia.

background: cambodia epicentre emergence plasmodium falciparum
drug resistance. much less known regarding drug susceptibility the
co-endemic plasmodium vivax. vitro drug assays determine the
parasite's intrinsic susceptibility, challenging implement for
p. vivax rarely performed.
objectives: evaluate evolution cambodian p. vivax susceptibility to
antimalarial drugs determine association putative markers drug 
resistance.
methods: vitro response three drugs used past decade cambodia was
measured 52 clinical isolates eastern cambodia collected 2015
and 2018 sequence copy number variation pvmdr1 pvcrt
genes analysed. pvmdr1 polymorphism also determined additional
250 isolates collected eastern cambodia 2014 2019.
results: among 52 cryopreserved isolates tested, susceptible 
three drugs, overall median ic50s 16.1 nm (iqr 11.4-22.3) chloroquine,
3.4 nm (iqr 2.1-5.0) mefloquine 4.6 nm (iqr 2.7-7.0) piperaquine. a
significant increase chloroquine piperaquine susceptibility observed
between 2015 2018, unrelated polymorphisms pvcrt pvmdr1.
susceptibility mefloquine significantly lower parasites single
mutation pvmdr1 compared isolates multiple mutations. proportion
of parasites single mutation genotype increased 2014 2019.
conclusions: p. vivax decreased susceptibility mefloquine associated
with introduction mefloquine-based treatment 2017-18.

© author(s) 2020. published oxford university press behalf the
british society antimicrobial chemotherapy.

doi: 10.1093/jac/dkaa092 
pmcid: pmc7303819
pmid: 32211790 

